EGFR-Mutationsanalyse beim nichtkleinzelligen Lungenkarzinom
作者： C. Tapia , S. Savic , M. Bihl , A. Rufle , I. Zlobec
DOI: 10.1007/S00292-009-1141-4
关键词: Lung cancer 、 Cancer research 、 Medicine 、 Mutation (genetic algorithm)
摘要: Hintergrund Einige Patienten mit einem nichtkleinzelligem Lungenkarzinom (NSCLC) sprechen hervorragend auf Tyrosinkinase-Hemmer (TKI) an. Eine somatische Mutation im epidermalen Wachstumsfaktor-Rezeptor (EGFR) gilt dabei als wichtiger pradikativer Faktor.
springer.com
core.ac.uk
sci-hub.se 参考文章(29)
Anne S. Tsao, Xi Ming Tang, Bradley Sabloff, Lianchun Xiao, Hisayuki Shigematsu, Jack Roth, Margaret Spitz, Waun Ki Hong, Adi Gazdar, Ignacio Wistuba, Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 1, pp. 231- 239 ,(2006) , 10.1016/S1556-0864(15)31573-2
Assessing EGFR mutations. The New England Journal of Medicine. ,vol. 354, pp. 526- ,(2006) , 10.1056/NEJMC052564
K. Schütze, Yilmaz Niyaz, M. Stich, A. Buchstaller, Noncontact Laser Microdissection and Catapulting for Pure Sample Capture Methods in Cell Biology. ,vol. 82, pp. 649- 673 ,(2007) , 10.1016/S0091-679X(06)82023-6
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
Yasushi Yatabe, Takashi Takahashi, Tetsuya Mitsudomi, Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Research. ,vol. 68, pp. 2106- 2111 ,(2008) , 10.1158/0008-5472.CAN-07-5211
Kathryn Smith Bilello, Susan Murin, Richard A Matthay, Epidemiology, etiology, and prevention of lung cancer. Clinics in Chest Medicine. ,vol. 23, pp. 1- 25 ,(2002) , 10.1016/S0272-5231(03)00057-1
Marc Ladanyi, William Pao, Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Modern Pathology. ,vol. 21, ,(2008) , 10.1038/MODPATHOL.3801018
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478
Lecia V. Sequist, Daphne W. Bell, Thomas J. Lynch, Daniel A. Haber, Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 25, pp. 587- 595 ,(2007) , 10.1200/JCO.2006.07.3585